



Correction to: Opioid analgesic dose and route conversion ratio studies: a scoping review to inform an eDelphi guideline

Mellar P. Davis¹ · Andrew Davies² · Mary Lynn McPherson³ · Akhila Reddy⁴ · Judith A. Paice⁵ · Eric Roeland⁶ · Declan Walsh⁷ · Sebastiano Mercadante⁸ · Amy Case⁹ · Robert Arnold¹⁰ · Eriko Satomi¹¹ · Gregory Crawford¹² · Eduardo Bruera¹³ · Carla Ripamonti¹⁴

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024

Correction to: Supportive Care in Cancer (2024) 32:542
<https://doi.org/10.1007/s00520-024-08710-0>

There are a couple of minor errors that I missed in Opioid Analgesic Dose and Route Conversion Ratio Studies: A Scoping Review to Inform an eDelphi Guideline:

1. Table 4 Opioid Potency Table ⁶⁵

You should refer to **Wen RY, Atayee RS, and Edmonds KP. A Comparison of Institutional Opioid Equianalgesia Tools: A National Study. *J Palliat Med.* 2022;25(11):1686-1691.**

2. Table 6 Morphine to Methadone Conversion. ⁴⁶

You should refer to **Wen RY, Edmonds KP, and Atayee RS. Comparing National Methadone Equianalgesic Tools. *J Pain Palliat Care Pharmacother.* 2023;37(3):246-250.**

3. Therefore, we compared our findings with previously published conversion tables. Wen and colleagues compared opioid potency ranges in 33 conversion tables collected through social media, organizational LISTSERV, and independent inquiries between May and September 2021. Rather than reference **64**.

Wen RY, Atayee RS, Edmonds KP. A Comparison of Institutional Opioid Equianalgesia Tools: A National Study. *J Palliat Med.* 2022;25(11):1686–1691.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s00520-024-08710-0>.

Extended author information available on the last page of the article

Authors and Affiliations

Mellar P. Davis¹ · Andrew Davies² · Mary Lynn McPherson³ · Akhila Reddy⁴ · Judith A. Paice⁵ · Eric Roeland⁶ · Declan Walsh⁷ · Sebastiano Mercadante⁸ · Amy Case⁹ · Robert Arnold¹⁰ · Eriko Satomi¹¹ · Gregory Crawford¹² · Eduardo Bruera¹³ · Carla Ripamonti¹⁴

✉ Mellar P. Davis
mdavis2@geisinger.edu

Andrew Davies
ANDAVIES@tcd.ie

Mary Lynn McPherson
mmcphers+rx.umaryland.edu@ccsend.com

Akhila Reddy
ASReddy@mdanderson.org

Judith A. Paice
JPaice1@nm.org

Eric Roeland
roeland@ohsu.edu

Declan Walsh
Declan.Walsh@atriumhealth.org

Sebastiano Mercadante
terapiadeldolore@lamaddalenanet.it

Amy Case
Amy.Case@RoswellPark.org

Robert Arnold
robert.arnold@mssm.edu

Eriko Satomi
esatomi@ncc.go.jp

Gregory Crawford
Gregory.Crawford@sa.gov.au

Eduardo Bruera
ebruera@mdanderson.org

Carla Ripamonti
carla.ripamonti@unibs.it

¹ Geisinger Medical Center, Danville, PA 17821, USA

² Trinity College Dublin, Dublin, Ireland

³ University of Maryland, Baltimore, MD, USA

⁴ Palliative Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA

⁵ Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

⁶ Oregon Health and Science University, Knight Cancer Institute, Portland, OR, USA

⁷ Atrium Health, Levine Cancer Center, Charlotte, NC, USA

⁸ La Maddalena Cancer Center, Palermo, Italy

⁹ Roswell Park Comprehensive Cancer Center, Rochester, NY, USA

¹⁰ Icahn School of Medicine at Mt Sinai, New York, NY, USA

¹¹ Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan

¹² Northern Adelaide Local Health Network, Adelaide, South Australia, Australia

¹³ University of Texas MD Anderson Cancer Center, Houston, TX, USA

¹⁴ Network Italiano Cure Di Supporto in Oncologia (NICSO), Università Degli Studi Di Brescia, Brescia, Italy